GigaGen
South San Francisco, US · Delaware corporation
GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$36.1M disclosed across 1 round · 2017
▶$36.1MraisedJul 2017 · 8 investors · PharmaceuticalsRule 506(b)
- Chuck WilsonDirector
- Carter KellerDirector
- David JohnsonExecutive Officer, Director
- Offering amount
- $36.1M
- Amount sold
- $36.1M
- Proceeds to insiders
- $3M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Companies competing with GigaGen for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $265K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $912.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $249.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $217.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.1M |
| National Science Foundation | Phase II | 2012 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $205.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $189.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $156.4K |
| Department of Energy | Phase I | 2012 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $201.6K |
| National Science Foundation | Phase I | 2011 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does GigaGen do?
- GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
- Who founded GigaGen?
- GigaGen was founded by David Johnson.
- How much funding has GigaGen raised?
- GigaGen has disclosed $36.1M raised across 1 round.
- Where is GigaGen headquartered?
- GigaGen is headquartered in South San Francisco, US.